RHEUMATOLOGY · SYSTEMIC LUPUS ERYTHEMATOSUS
Obexelimab systemic lupus erythematosus study
A Phase 2 study evaluating obexelimab in adults with active systemic lupus erythematosus.
Study overview
This randomized, double-blind, placebo-controlled Phase 2 study evaluates obexelimab in adults with active systemic lupus erythematosus, commonly called SLE or lupus. Participants continue permitted background nonbiologic standard-of-care treatment while receiving weekly subcutaneous study injections for the protocol-defined treatment period. Randomization assigns the study group, and masking means participants and most study personnel do not know whether obexelimab or placebo is given during the controlled portion.
What researchers are evaluating
Researchers are examining safety, tolerability, and changes in lupus disease activity. Assessments may include physical examinations, symptom and medication reviews, blood and urine tests, disease-activity scoring, electrocardiograms, and monitoring for adverse events. Obexelimab is investigational; its benefits and risks for SLE are not fully established. Background therapy requirements and medication adjustments are governed by the protocol and reviewed by qualified study staff. Placebo is an inactive comparator used to help determine whether observed changes are related to the investigational treatment.
Considering participation
Potential eligibility may depend on age, confirmed SLE, current disease activity, laboratory findings, background therapy, prior treatments, vaccination history, pregnancy-related requirements, infections, and other health conditions. The official protocol controls all eligibility decisions. Study and local-site status can change, so a public listing does not confirm that enrollment is open.
Participation is voluntary, and informed consent covers study groups, procedures, foreseeable risks, possible benefits, alternatives, confidentiality, and the right to withdraw. Do not submit medical records or other sensitive information in an initial message.